Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Portfolio prioritization tactics in a smaller-sized organization
Read the full interview with Corky LaVallee from Dynavax Technologies, and learn more about portfolio management and project prioritization strategies.
1. What is the main difference in portfolio management and prioritization between big companies and smaller-sized organizations?
The most obvious difference is that in big companies the portfolios are so large that no one person can get their arms around the potential opportunities and trade-offs between costs, ROIs and risks in the various options available for investing. In addition, there is usually intense competition for resources between the various assets.
2. How to be sure that the right projects are being performed? What are the key steps for successful prioritization?
"Right" is relative to the company's situation and objectives. The bottom line is that every company has finite resources, usually less than the ways they can invest those resources. If you can advance every compound you have, you generally will; if not, you want to invest your constrained resources in a way that maximizes your potential return. To do that, you need to estimate the costs associated with moving the compound forward, the probability of success for each step (or risk of failure), and the overall value of that asset, which is influenced by things like unmet medical need, size of the market, the competition, etc.
3. What are the main pitfalls that can occur in the process of prioritization?
I've already touched on some of them. Other risks are imprecision of methodology, differences in effectiveness of communication between teams, personal biases of the management team members, and going through a rigorous prioritization process and then doing everything any how.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.